RPH3A

Across TCGA pan-cancer cohorts, RPH3A mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RPH3A data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher RPH3A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RPH3A expression acts as an unfavorable survival marker, although some lineages such as GBM and PDAC show a favorable association.

GBM and PDAC are the cancer types where RPH3A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.848	0.648	.007	3	view →
PDAC	DFS	Tertile	III,IV	0.576	0.236	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RPH3A–GBM (DFS)

Open the GBM breakdown →